BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 87197)

  • 1. Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors.
    Glass WF; Moore JB
    Biochem Pharmacol; 1979 Apr; 28(7):1107-12. PubMed ID: 87197
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle.
    Polson JB; Krzanowski JJ; Anderson WH; Fitzpatrick DF; Hwang DP; Szentivanyi A
    Biochem Pharmacol; 1979 Apr; 28(8):1391-5. PubMed ID: 87201
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential effects of cyclic nucleotides and their analogs and various agents on cyclic GMP-specific and cyclic AMP-specific phosphodiesterases purified from guinea pig lung.
    Davis CW; Kuo JF
    Biochem Pharmacol; 1978 Jan; 27(1):89-95. PubMed ID: 202285
    [No Abstract]   [Full Text] [Related]  

  • 4. Selective inhibition of rat lung cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase by cyclic nucleotides and their analogues and various drugs [proceedings].
    Butt NM; Saeed SA; Collier HO
    Biochem Soc Trans; 1980 Jun; 8(3):380-1. PubMed ID: 6249674
    [No Abstract]   [Full Text] [Related]  

  • 5. Methylxanthine inhibitors of phosphodiesterases.
    Wells JN; Miller JR
    Methods Enzymol; 1988; 159():489-96. PubMed ID: 2457788
    [No Abstract]   [Full Text] [Related]  

  • 6. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some cardio- or vaso-active butenolide derivatives.
    Némoz G; Prigent AF; Picq M; Pacheco H
    Biochem Pharmacol; 1982 Nov; 31(21):3353-8. PubMed ID: 6293510
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction.
    Ahluwalia GS; Rhoads AR
    Biochem Pharmacol; 1982 Mar; 31(5):665-9. PubMed ID: 6177320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
    Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
    Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of lung cyclic AMP- and cyclic GMP-phosphodiesterases by flavonoids and other chromone-like compounds.
    Ruckstuhl M; Landry Y
    Biochem Pharmacol; 1981 Apr; 30(7):697-702. PubMed ID: 6264919
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
    Zhu WH; Majluf-Cruz A; Omburo GA
    Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase inhibitors as tools in cyclic nucleotide research: a precautionary comment.
    Wells JN; Kramer GL
    Mol Cell Endocrinol; 1981 Jul; 23(1):1-9. PubMed ID: 6167475
    [No Abstract]   [Full Text] [Related]  

  • 13. Flavonoids are selective cyclic GMP phosphodiesterase inhibitors.
    Ruckstuhl M; Beretz A; Anton R; Landry Y
    Biochem Pharmacol; 1979; 28(4):535-8. PubMed ID: 218594
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of human lung cyclic nucleotide phosphodiesterases by proxyphylline, theophylline and their metabolites.
    Selvig K; Bjerve KS
    Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):250-2. PubMed ID: 6291318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro.
    Rusin LJ; Duell EA; Voorhees JJ
    J Invest Dermatol; 1978 Aug; 71(2):154-6. PubMed ID: 210235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioprotection of mouse intestine by inhibitors of cyclic AMP phosphodiesterase.
    Lehnert S
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):825-33. PubMed ID: 91600
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
    Ilien B; Ruckstuhl M; Landry Y
    J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic nucleotide phosphodiesterase activities of the embryonic chick ovary.
    Teng CT; Buchler B; Teng CS
    Gen Comp Endocrinol; 1981 Aug; 44(4):409-17. PubMed ID: 6167486
    [No Abstract]   [Full Text] [Related]  

  • 19. Measurements of cyclic AMP and cyclic GMP phosphodiesterase activity in isolated tubular segments.
    Jackson BA; Edwards RM; Dousa TP
    Kidney Int; 1980 Oct; 18(4):512-8. PubMed ID: 6164816
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of divalent metals on the specificity of inhibitors of the cyclic nucleotide phosphodiesterases from bovine heart.
    Donnelly TE; Barron B
    Biochim Biophys Acta; 1981 Jan; 657(1):168-78. PubMed ID: 6260197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.